This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of vagina
C3_VAGINA
Vaginal neoplasm: Tumors or cancer of the VAGINA.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleonly females |
293145 |
2. Check conditionsNone |
293145 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
82 |
4. Check minimum number of eventsNone |
82 |
5. Include endpointsNone |
82 |
6. Filter based on genotype QC (FinnGen only) |
79 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of vagina
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of vagina, including Hilmo
- malignant neoplasm of female genital organs
- malignant neoplasm of female genital organs, including Hilmo
- Solid cancers
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 79 | 79 | - |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | - |
| Median age at first event (years) | 64.78 | 64.78 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 82
- Matched controls
- 820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
128
Kela drug reimbursment
Cancers of female genital organs
+∞
51.6
44
*
C52.91
ICD-10 Finland
Squamous cell carcinoma of the vagina
+∞
50.3
43
*
LEB00
NOMESCO Finland
Biopsy of vagina
203.9
48.0
46
5
8070/3-C52.9
ICD-O-3
Squamous cell carcinoma, NOS, of vagina, NOS
+∞
47.6
41
*
A03FA01
ATC
metoclopramide; systemic, rectal
18.8
42.1
55
80
H02AB02
ATC
dexamethasone; systemic
99.6
33.4
35
6
C52
ICD-10 Finland
Malignant neoplasm of vagina
+∞
31.2
28
*
WF002
NOMESCO Finland
Radical radiotherapy
146.7
28.8
29
*
A04AA01
ATC
ondansetron; systemic, rectal
81.5
28.7
31
6
ULA02
NOMESCO Finland
Kolposcopy
11.6
26.9
38
57
C52.90
ICD-10 Finland
Malignant neoplasm of vagina without histologic examination
+∞
24.1
22
*
N02AA05
ATC
oxycodone; systemic
9.8
24.1
41
76
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
23.0
21
*
XX3DW
NOMESCO Finland
Time consuming IT work
32.7
20.8
27
12
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
20.7
19
*
WZC00
NOMESCO Finland
Treatment plan or consultation
8.3
20.5
55
161
L03AA13
ATC
pegfilgrastim; parenteral
+∞
19.5
18
*
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
121.9
18.4
19
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
121.9
18.4
19
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
18.4
17
*
C52.99
ICD-10 Finland
Malignant tumor of the vagina, unspecified histology
+∞
18.4
17
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
8.0
18.4
34
67
A04AA02
ATC
granisetron; systemic, transdermal
+∞
17.3
16
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
211.2
17.2
17
*
JN4BD
NOMESCO Finland
Extensive body CT
23.6
16.9
24
14
JN4AD
NOMESCO Finland
Body CT examination
16.9
16.6
27
23
UKC02
NOMESCO Finland
Cystoscopy
7.8
16.3
29
54
A04AD12
ATC
aprepitant; systemic
+∞
16.2
15
*
B01AB10
ATC
tinzaparin; parenteral
7.6
15.2
27
50
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
15.0
14
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
15.0
14
*
Z51.5
ICD-10 Finland
Palliative care
18.3
13.7
21
15
C52.92
ICD-10 Finland
Adenocarcinoma of the vagina
+∞
12.8
12
*
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
18.6
12.5
19
13
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
5.3
12.5
53
210
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
16.1
11.9
19
15
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
6.4
11.8
24
50
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
11.7
11
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
11.7
11
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
11.7
11
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
11.7
11
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
22.5
10.7
15
8
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
125.4
10.7
11
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
125.4
10.7
11
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
10.6
10
*
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
+∞
10.6
10
*
LEC00
NOMESCO Finland
Partial excision of vagina
+∞
10.6
10
*
130
Kela drug reimbursment
Malignant tumour
+∞
10.6
10
*
YX9VG
NOMESCO Finland
Other MRI eamination with high intensity magnet for dose design of radiotherapy
+∞
9.6
9
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
9.6
9
*
J01EA01
ATC
trimethoprim; systemic
4.0
8.8
48
214
WW500
NOMESCO Finland
Blood transfusion
23.1
8.8
12
6
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
99.9
8.6
9
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
8.5
8
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
8.5
8
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
8.5
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.5
8
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
8.5
8
*
X77
ICPC
Malignant neopl genital female other
+∞
8.5
8
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
8.5
8
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
19.8
8.4
12
7
LEB10
NOMESCO Finland
Excision of lesion of vagina
37.4
8.3
10
*
JN3AD
NOMESCO Finland
Abdominal CT examination
5.0
7.9
20
50
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
20.8
7.8
11
6
A06AH03
ATC
naloxegol; oral
87.7
7.5
8
*
ZZR00
NOMESCO Finland
Flap of skin
87.7
7.5
8
*
D39.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other female genital organs
87.7
7.5
8
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
YL1CD
NOMESCO Finland
Very extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.4
7
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.4
7
*
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
4.9
7.4
19
48
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
22.4
7.3
10
5
L02BG04
ATC
letrozole; oral
33.2
7.3
9
*
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
5.0
6.9
17
41
N93.9
ICD-10 Finland
Abnormal uterine and vaginal bleeding, unspecified
18.7
6.9
10
6
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
6.9
6.9
17
30
B01AB05
ATC
enoxaparin; parenteral
3.3
6.7
39
175
WZC30
NOMESCO Finland
Teaching
4.5
6.7
19
52
D70.82
ICD-10 Finland
Drug-induced neutropenia
75.5
6.5
7
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.2
6.5
17
33
TPX10
NOMESCO Finland
Implantation of vascular injection port
29.2
6.4
8
*
8140/3-C52.9
ICD-O-3
Adenocarcinoma, NOS, of vagina, NOS
+∞
6.3
6
*
A79
ICPC
Malignancy NOS
+∞
6.3
6
*
L03AA02
ATC
filgrastim; parenteral
+∞
6.3
6
*
115
Kela drug reimbursment
Breast cancer
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
6.3
6
*
8077/2-C52.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of vagina, NOS
+∞
6.3
6
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
6.3
6
*
TJF80
NOMESCO Finland
Ostomy education
+∞
6.3
6
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
+∞
6.3
6
*
C529, 8085, 3
ICD-O-3
+∞
6.3
6
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
6.1
51
279
TKC20
NOMESCO Finland
Catheterisation of bladder
6.6
6.0
15
27
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
53
266
3.81
7.90
5.7
3.1
—
—
—
0
0
59
322
3.97
7.66
4.5
2.3
—
—
estimate
—
0
0
31
116
3.69
7.11
2.3
1.8
—
—
—
0
0
24
87
3.49
5.64
2.4
1.8
—
—
—
0
0
23
83
3.46
5.43
14.9
7.0
—
—
—
0
0
24
92
3.27
5.13
2.3
1.8
—
—
—
0
0
41
215
2.81
5.02
4.3
2.9
0.49
0.37
e6/l
0.34
36
147
34
164
2.83
4.84
2.6
1.4
—
—
—
0
0
42
229
2.71
4.69
9.7
4.0
0.00
0.00
estimate
-0.00
12
68
12
26
5.22
4.26
1.7
1.6
—
—
—
0
0
15
48
3.60
4.17
1.9
1.6
48.67
64.71
ml/min/173m2
—
6
17
10
18
6.16
4.12
1.1
1.1
120.90
274.80
pmol/l
—
10
18
63
438
2.89
4.11
8.9
4.1
0.00
0.00
estimate
-0.00
13
71
22
92
2.90
3.98
9.8
4.2
102.09
104.45
mmol/l
0.99
22
92
11
24
5.12
3.91
1.4
1.3
—
—
—
0
0
61
428
2.66
3.72
8.9
4.0
0.00
0.00
estimate
—
10
72
30
156
2.46
3.50
4.4
1.9
—
—
—
0
0
13
41
3.57
3.24
1.7
1.5
—
—
—
0
0
60
435
2.41
3.13
8.9
4.0
0.00
0.00
estimate
-0.00
13
75
56
396
2.31
3.07
9.7
4.9
1.21
1.22
mmol/l
0.63
51
356
8
18
4.80
2.87
1.6
1.7
95.63
96.44
%
—
8
18
15
61
2.79
2.81
2.6
1.3
—
—
—
0
0
7
14
5.35
2.79
1.4
1.6
—
—
—
0
0
33
198
2.12
2.64
7.0
4.1
1.02
1.02
kg/l
0.20
27
136
10
31
3.53
2.62
2.2
1.5
—
—
—
0
0
17
79
2.45
2.45
2.9
1.9
388.88
367.99
nmol/l
0.12
17
74
6
12
5.30
2.45
1.8
1.8
3.30
2.95
g/l
—
6
12
6
13
4.89
2.31
1.5
1.2
—
—
—
0
0
24
136
2.08
2.18
4.9
2.8
1.32
1.35
e6/l
0.01
16
62
43
300
1.91
2.16
4.4
3.8
87.99
129.55
ng/l
0.12
33
220
6
17
3.72
1.87
1.5
1.1
—
—
—
0
0
43
314
1.78
1.76
10.2
3.8
0.00
0.00
estimate
—
9
52
63
713
0.50
1.73
7.3
6.9
39.01
39.70
mmol/mol
0.26
58
675
26
168
1.80
1.57
1.6
1.8
1.52
1.41
mg/l
0.09
19
139
6
24
2.61
1.33
1.3
1.1
—
—
—
0
0
5
20
2.59
1.17
1.4
2.3
—
—
—
0
0
9
47
2.03
1.06
6.0
2.4
1.03
1.29
%
—
9
47
9
48
1.98
1.04
5.3
5.1
1.73
1.24
%
—
9
48
9
48
1.98
1.04
4.8
5.0
0.73
0.63
%
—
9
48
11
62
1.89
1.00
2.3
4.3
391.82
193.39
ng/l
0.24
11
56
8
43
1.95
0.90
13.0
2.8
23.57
24.66
mmol/l
—
8
43
19
131
1.59
0.89
5.1
3.1
1.10
5.42
e6/l
2.17
11
58
69
739
0.58
0.87
5.8
5.5
5.92
5.92
mmol/l
0.02
63
690
0
25
0.00
0.80
0.0
1.1
—
0.00
—
0
25
0
25
0.00
0.80
0.0
1.1
—
0.00
—
0
25
0
26
0.00
0.80
0.0
1.1
—
0.00
—
0
26
5
23
2.25
0.77
2.2
1.6
—
—
—
0
0
7
38
1.92
0.76
1.6
1.1
—
—
—
0
0
7
42
1.73
0.70
1.6
1.2
—
—
—
0
0
49
424
1.39
0.69
2.9
2.8
—
—
—
0
0
5
28
1.84
0.67
1.2
1.6
—
—
—
0
0
10
66
1.59
0.55
3.5
3.3
—
—
—
0
0
9
62
1.51
0.55
1.7
1.5
—
—
—
0
0
12
165
0.68
0.53
1.2
1.4
26.58
31.92
iu/ml
—
5
57
77
787
0.65
0.42
54.2
21.1
92.10
91.01
fl
0.82
77
778
77
787
0.65
0.42
54.4
21.3
37.38
39.65
%
4.44
77
778
77
787
0.65
0.42
54.8
21.3
122.60
132.13
g/l
6.19
77
776
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
12
156
0.73
0.39
1.2
1.3
3.98
11.71
u/ml
—
5
52
11
81
1.41
0.38
12.8
2.4
1.05
1.04
mmol/l
0.08
11
70
42
386
1.18
0.26
2.0
2.2
88.79
106.11
pmol/l
2.06
25
174
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
6
50
1.22
0.20
17.2
5.3
26.47
25.38
mmol/l
—
6
50
63
606
1.17
0.18
48.7
18.6
330.31
330.00
g/l
0.10
63
606
21
191
1.13
0.13
1.2
1.3
0.78
1.80
u/ml
—
10
46
24
221
1.12
0.13
10.2
3.4
0.00
0.00
estimate
—
9
55
11
126
0.85
0.12
1.0
1.5
—
—
—
0
0
58
597
0.90
0.10
41.6
17.5
14.42
13.61
%
2.75
58
592
5
44
1.15
0.10
3.2
5.0
28.42
25.16
mmol/l
—
5
44
5
46
1.09
0.10
1.4
1.0
—
—
—
0
0
77
774
0.92
0.10
40.9
18.1
77.87
70.22
umol/l
0.52
77
762
29
300
0.95
0.04
3.2
3.8
7.68
3.62
mg/mmol
0.59
19
176
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
4.16
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1754.20
—
0
5
0
7
0.00
-0.00
0.0
1.9
—
43.86
—
0
7
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
71.00
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
76
761
0.98
-0.00
38.4
16.9
4.02
3.95
mmol/l
1.71
76
745
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
76
761
0.98
-0.00
38.7
16.7
138.50
139.91
mmol/l
3.79
76
746
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_VAGINA – Malignant neoplasm of vagina
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).